Challenges and Outcomes of the First Stem Cell Transplant Program in Tanzania, East Africa.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rwezaula Stella, Yonazi Mbonea, Panchal Amey, Dhoot Ashish, Mathew Jemy, Tony Sonu, Rao Sandeep, Muhoka Peter, Mahfudh Samira, Budodi Neema, Kasubi Mabula, Ndobho Flora, Kakumbula Helena, Luhulla Koga, Kapesa Linda, Tungaraza Heri, Nyagabona Sarah, Shayo Agnes, Seleki Felister, Mtenga Janeth, Mwamtemi Khadija, Suko Musa, Mbughi Isaac, Shirima Mariana, Mkisi Alfayo, Ally Rahma, Kyaruzi Malselina, Arola Myaka Else, Matiku Johari, Nyamwaira Mariam, Nair Saranya, Asokan Aswathy, Kumar Goutham, Badavath Raj, Swai Hedwiga, Museru Lawrence, Ajaikumar B S, Beda Deogratius, Jadhav Sachin
Аннотация
MATERIALS AND METHODS: Information and data were collected on the processes which had been implemented for starting the HSCT program at MNH. The details of the collaborations, training, infrastructure development, and acquisition of the biomedical equipment, as well as the actual process for HSCT, as well as the outcomes of treatment are described. Observations. The project has been detailed in 4 stages for ease of description: Stage 1: Preparatory work which was performed by the Government of Tanzania, as well as the administrators and clinicians from MNH (July 2017-September 2021). Stage 2: Exploratory gap analysis by the teams from MNH and International Haematology Consortium of HCG Hospital, India (HCG-IHC) in October 2021. Stage 3: Activities for closure of gaps (November 2021). Stage 4: Stem Cell Transplantation Camps (November 2021 to March 2022). 11 peripheral blood stem cell transplants were done in two camps, November 2021 (5 patients), and February 2022 (6 patients). 10 patients underwent autologous peripheral blood stem cell transplantation for multiple myeloma and 1 for lymphoma. The median duration of hospital stay was 19 ± 6 days. The median time for neutrophil engraftment, it was on 8.8 ± 0.8 days, and for platelet engraftment was 9.6 ± 2.4 days. Progression-free survival was 100%, and there was no mortality.
CONCLUSION: Commonalities in the socioeconomic challenges in developing countries can be leveraged to create robust HSCT programs in other developing countries.